MG0003

The purpose of this study is to assess the clinical efficacy, safety and tolerability of Rozanolixizumab, which is a type of antibody that helps breakdown harmful auto-antibodies in generalized myasthenia gravis patients.

Rozanolixizumab will be administered through a 30-minute subcutaneous infusion (i.e. a small needle inserted under the skin) every week for 6 weeks, with a two month observation period. Overall, participants may be in the research study for about 19 weeks, with the option to continue for up to about 1 year in an open label extension study.

Principal Investigator: Suraj Muley, MD